drugset / Trial / NCT05914389

Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer

NCT05914389

RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to elucidate the regression effects of neoadjuvant chemotherapy combined with immunotherapy and adjuvant therapy in locally advanced MSS colon cancer.

Timeline

Start
2023-08
Primary completion
2025-08
Completion
2030-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Clostridium butyricum Other / unclassified 160 mg Oral
Subject Envafolimab Monoclonal antibody 100 mg
Background Capecitabine Small molecule 1000 mg/m2 Oral
Background Oxaliplatin Small molecule 130 mg/m2

Indications